QCZ484

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HypertensionHypercholesterolaemiaHypertension (HTN)

157 competitors in Hypertension

#DrugCompanyPhaseTrials

1

Baxfendy

AstraZeneca

Phase 3

32

Foundayo

Eli Lilly

Phase 3

33

Nitrostat

VViatris Specialty LLC

Phase 3

54

Alka-Seltzer

AAbbott

Phase 3

15

Minocycline /d

UUniversity of Florida

Phase 3

16

SGLT2

PProf. Dr. med. Ingo Eitel

Phase 3

17

QCZ484

Novartis

Phase 2

28

Avastin

Roche

Preclinical

19

Winrevair

Merck & Co.

Preclinical

—10

Alphagan

AbbVie

Preclinical

—Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hypertension2 trials

A Randomized, Double-blind, Placebo-controlled, Multicenter, 12 Months Treatment Duration, Dose Finding Study, to Evaluate Efficacy, Safety and Pharmacodynamics of QCZ484 in Mild to Moderate Hypertensive Patients

Active, not recruiting·Novartis·Phase 2·NCT06857955·396 enrolled

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered QCZ484 in Healthy Subjects and Subjects With Mild Hypertension

Completed·Novartis·Phase 1·NCT06905327·56 enrolled

Hypertension (HTN)1 trial

A Multicenter Open-label Extension Study to Evaluate Long-term Safety and Efficacy of QCZ484 in Hypertensive Patients.

Recruiting·Novartis·Phase 2·NCT07543120·323 enrolled

Hypercholesterolaemia1 trial

A Multicenter, Randomized, Double-blind, Factorial Design Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of HDY015 Administered as a Free Combination of QCZ484 and Inclisiran Compared to QCZ484, Inclisiran, and Placebo in Participants With Hypertension and Concomitant Hypercholesterolemia

Recruiting·Novartis·Phase 2·NCT07610278·120 enrolled

Details

Drug Info

Related News